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In a recent editorial, Dr Van Poznak addresses the 
important issue of managing bone health in breast cancer 
patients receiving adjuvant treatment with an aromatase 
inhibitor [1]. Based on the published results of three 
clinical trials using risedronate [2,3] or ibandronate [4], it 
is concluded that oral bisphosphonates may be con-
sidered a supportive therapy to treat or prevent osteo-
porosis in breast cancer patients receiving aromatase 
inhibitor adjuvant treatment.
We would like to comment on the results of those trials 
summarised in Table 1 of the editorial [1], focusing on 
patients with normal bone mineral density (BMD) or 
mild osteopaenia before starting treatment.
All three trials have shown that patients with normal 
BMD before starting treatment with anastrozole are at 
very low risk to develop osteoporosis, having a change in 
BMD less than –6% measured at 2 years in both the 
lumbar spine and hip, without any pharmacologic inter-
ven  tion apart from receiving vitamin D and calcium 
supple  ments [2-4]. Th   e risk of osteoporosis is minimal and 
only a few patients might move to the osteopaenic region.
Considering the grey zone of treatment decisions in the 
management of patients with osteopaenia, we agree those 
trials provide very useful clinical data on the need for 
pharmacologic intervention and the eﬀ  ectiveness of oral 
bisphosphonates. Even though the BMD loss is less than 
–4% in both the lumbar spine and hip at 2 years under 
anastrozole treatment, the addition of oral bisphos-
phonates results in a change of up to +5.7% in BMD that 
is statistically signiﬁ  cant in all three trials – preventing 
eﬀ   ectively the development of osteoporosis. Further-
more, the mixed models analysis of the randomised arms 
in the ARBI trial [3] examining the percentage change 
from baseline in hip and lumbar spine BMD values 
suggests that higher baseline BMD values correspond to 
smaller changes at both 12 and 24 months, whereas 
patients’ smaller BMD values at baseline exhibited a 
higher trend of BMD increase. In other words, patients 
starting treatment with anastrozole are not all at the 
same risk for bone loss, and also they respond to a 
diﬀ   erent extent to pharmacologic interventions – 
pretreatment BMD estimation is an important factor in 
management decisions.
In conclusion, we estimate that all trials provide 
evidence supporting the use and eﬀ   ectiveness of oral 
bisphosphonates in patients already having BMD in the 
region of severe osteopaenia/osteoporosis when starting 
treatment with an aromatase inhibitor. On the contrary, 
for patients with normal BMD or mild osteopaenia at 
baseline, general preventive measures and BMD 
evaluation during follow-up visits seem to be adequate 
management since these patients are at low risk of 
developing severe osteopaenia or osteoporosis.
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